N4 Pharma PLC

Chart & Performance

D1W1MN

P/E

—

P/S

628.61

EPS

—

Div Yield, %

—

Shrs. gr., 5y

27.75%

Rev. gr., 5y

-60.78%

Revenues

+272.86%

Net income

-1m

L-16.57%

CFO

-1m

L+45.98%

Dividend

May 19, 19970.005625 GBP/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

N4 Pharma Plc, a specialist pharmaceutical company, develops novel silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.

URL

https://www.n4pharma.com/

IPO date

Jun 07, 2005

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title GBP in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title GBP in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT